According to the news of "Xinhua Medical" WeChat public account on March 7, Xinhua Medical In vitro diagnostic technology branch successfully rolled off the first batch of XP20 SGH-200 saccharin analyzers in February 2022, filling the gap in this field of Shandong Xinhua Medical Device Co., Ltd., which also means that the glycosylated hemoglobin analyzer is officially listed, adding new impetus to further enhance the competitiveness of the enterprise in the in vitro diagnostic market and brand building.
Diabetes is one of the major chronic diseases with high incidence in the world, and the number of diabetics in the mainland has now reached 130 million, accounting for about 1/4 of the total number of diabetic people in the world, and is increasing at a rate of at least 15,000 people per day, increasing by more than 5.5 million per year, and it is predicted that the total number of diabetes people on the mainland will soar to 160 million by 2025.
With its advantages of good stability, simplicity and ease, the glycosylated hemoglobin analyzer has been widely used in clinical diagnosis, treatment monitoring and prognosis assessment of diabetes in recent years. However, the market share of domestic brands of glycosylated hemoglobin instruments is low, which provides a large space for development for Xinhua Medical. Xinhua Medical grasped the opportunity to establish in vitro diagnostic brand products and strive to have an unshakable place in the domestic market.